Patients may begin to feel migraine pain relief in as little as 10 minutes (17% of patients vs. 5% for placebo).*
60% of patients experienced migraine pain relief 2 hours after administration (vs. 21% for placebo).1 Results from a single-attack, parallel group design study, where six different doses of sumatriptan injection, including 3 mg, were compared (n=30 in each group) with placebo (n=62).
*Time to onset and degree of pain relief varies by patient.
†Store between 68°F and 77°F. Excursions permitted between 59°F and 86°F.
Proportion of patients with migraine pain relief by time with a 3 mg dose of sumatriptan injection (n=30).1 ‡
‡Results from a single-attack, parallel group design study, where six different doses of sumatriptan injection, including 3 mg, were compared (n=30 in each group) with placebo (n=62).
Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine treated, reconsider the diagnosis before Zembrace® SymTouch® is administered to treat subsequent attacks. Zembrace® SymTouch® is not indicated for the prevention of migraine attacks, and is contraindicated in patients with a history of hemiplegic or basilar migraines.
Upsher-Smith Laboratories, LLC takes pride in providing attentive customer service, having strong industry relationships and being dedicated to uninterrupted supply.
Zembrace® SymTouch® continues our commitment to ensure you have a variety of medication options that can address the unique needs of migraine patients.
Sign up today to learn more about Zembrace® SymTouch®.